Abstracts tagged "juvenile dermatomyositis and pediatric rheumatology"

Abstract Number: 1276 • 2017 ACR/ARHP Annual Meeting
Nail Fold Capillary Changes Are Associated with Pulmonary, but Not with Cardiac Involvement in Juvenile Dermatomyositis
Zoltán Barth^1,2,3, Thomas Schwartz^2,4, Berit Flatø^5,6, Akos Koller^7,8, May Brit Samersaw-Lund⁹, Ivar Sjaastad^10,11 and Helga Sanner⁶, ¹Bjorknes College, Oslo, Norway, ²Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, ³Medical School, University of Pecs, Institute for Translational Medicine, Pecs, Hungary, ⁴Institute for Experimental Medical Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, ⁵Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁷University of Physical Education, Institute of Natural Sciences, Budapest, Hungary, ⁸Medical School, University of Pecs, Department of Neurosurgery, Pecs, Hungary, ⁹Oslo University Hospital, Rikshospitalet, Department of Respiratory Medicine, Oslo, Norway, ¹⁰Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ¹¹Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway, Oslo, Norway
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease of unknown origin, characterised primarily by cutaneous rashes and symmetrical weakness of the proximal skeletal muscles.…
Abstract Number: 1280 • 2017 ACR/ARHP Annual Meeting
Clinical Outcomes of Juvenile Dermatomyositis Patients Treated with TNF-Inhibitors: A Retrospective Chart Review Katelyn Banschbach1, Ellen Go1 and Stacey Tarvin2, 1Indiana University School of Medicine, 2riley Hospital for Children, Indiana University
Katelyn Banschbach¹, Ellen Go² and Stacey Tarvin³, ¹Indiana University School of Medicine, Indianapolis, IN, ²Pediatrics, Indiana University School of Medicine, Indianapolis, IN, ³Riley Hospital for Children, Indiana University, Indianapolis, IN
Background/Purpose: To analyze the clinical outcomes of TNF-inhibitors as a steroid-sparing agent in the treatment of juvenile dermatomyositis (JDM). Methods: We performed a retrospective chart…
Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Arya Kadakia¹, Amer Khojah², Gabrielle A. Morgan^3,4, Megan L. Curran⁵, Irwin Benuck⁶, Chinag-Ching Huang¹, Dong Xu⁷ and Lauren M. Pachman^8,9, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁴Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Pediatric Rheumatology, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Division of Cardiology, Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, IL, ⁷Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁸Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…
Abstract Number: 87 • 2017 Pediatric Rheumatology Symposium
Assessment of Endothelial Dysfunction and Atherogenic Risk Factors in Children with Juvenile Dermatomyositis
Dawn Wahezi¹, Emily Liebling², Jillian Parekh², Marija Dionizovik-Dimanovski¹, Jaeun Choi³ and Qi Gao³, ¹Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ²Pediatrics, Children's Hospital at Montefiore, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Endothelial pulse amplitude testing (Endo-PAT) measures changes in vascular tone by post-occlusive hyperemic response. A reduced hyperemic response suggests endothelial dysfunction and serves as…
Abstract Number: 1364 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
Raquel Campanilho-Marques^1,2,3,4, Claire Deakin⁵, Stephanie Simou⁶, Lucy R Wedderburn^2,7,8, Clarissa Pilkington^7,9 and on behalf of Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, ²Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Rheumatology, Santa Maria Hospital, CHLN, Lisbon, Portugal, ⁴Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal, ⁵Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ⁶Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁷Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Some patients with juvenile dermatomyositis (JDM) have a disease course which is refractory to multiple drug treatments. There is evidence that prolonged disease activity…
Abstract Number: 53 • 2015 ACR/ARHP Annual Meeting
Associations Between Race and Income Disparity on Morbidity in Juvenile Dermatomyositis
Kathryn Phillippi¹, Mark Hoeltzel², Angela Byun Robinson^3,4, Susan Kim⁵ and CARRA investigators, ¹Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and Children’s Hospital / Case Medical Center, Cleveland, OH, ²Rheumatology Division, University of Michigan Mott Children's Hospital, Ann Arbor, MI, ³Pediatrics, Rainbow Babies & Children's Hospital / Case Medical Center, Cleveland, OH, ⁴Pediatric Rheumatology, Rainbow Babies and Childrens Hospital, Cleveland, OH, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA
Disclosure: T32 grant: the National Institutes of Health under Ruth L. Kirschstein National Research Service Award T32 AR007505 from the NIH NIAMS. The CARRA Registry is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].